Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial

医学 偏头痛 安慰剂 双盲 临床试验 传统医学 内科学 药理学 替代医学 病理
作者
Shengyuan Yu,Byung–Kun Kim,Aihong Guo,Manho Kim,Mingjie Zhang,Zhen Wang,Jianguang Liu,Heui‐Soo Moon,Ge Tan,Qian Yang,Donnie McGrath,Michael Hanna,David Stock,Gao Yanfei,Robert Croop,Zhihong Lu
出处
期刊:Lancet Neurology [Elsevier]
卷期号:22 (6): 476-484 被引量:13
标识
DOI:10.1016/s1474-4422(23)00126-6
摘要

No acute treatments targeting calcitonin gene-related peptide (CGRP) have been approved for use in China or South Korea. We aimed to compare the efficacy and safety of rimegepant-an orally administered small molecule CGRP antagonist-with placebo in the acute treatment of migraine among adults in these countries.This double-blind, randomised, placebo-controlled, multicentre phase 3 trial was done at 86 outpatient clinics at hospitals and academic medical centres (73 in China and 13 in South Korea). Participants were adults (≥18 years) with at least a 1-year history of migraine who had two to eight moderate or severe attacks per month and fewer than 15 headache days per month within the 3 months before the screening visit. Participants were randomly assigned (1:1) to 75 mg rimegepant or placebo to treat a single migraine attack of moderate or severe pain intensity. Randomisation was stratified by the use of preventive medication and by country. The allocation sequence was generated and implemented by study personnel using an interactive web-response system accessed online from each study centre. All participants, investigators, and the sponsor were masked to treatment assignment. The coprimary endpoints of freedom from pain and freedom from the most bothersome symptom (nausea, phonophobia, or photophobia) 2 h after dosing were assessed in the modified intention-to-treat (mITT) population (randomly assigned participants who took study medication for a migraine attack of moderate or severe pain intensity, and provided at least one efficacy datapoint after treatment) using Cochran-Mantel Haenszel tests. Safety was assessed in all participants who received rimegepant or placebo. The study is registered with ClinicalTrials.gov, number NCT04574362, and is completed.1431 participants were randomly assigned (716 [50%] to rimegepant and 715 [50%] to placebo). 668 (93%) participants in the rimegepant group and 674 (94%) participants in the placebo group received treatment. 1340 participants were included in the mITT analysis (666 [93%] in the rimegepant group and 674 [94%] in the placebo group). 2 h after dosing, rimegepant was superior to placebo for pain freedom (132 [20%] of 666 vs 72 [11%] of 674, risk difference 9·2, 95% CI 5·4-13·0; p<0·0001) and freedom from the most bothersome symptom (336 [50%] of 666 participants vs 241 [36%] of 674 participants, 14·8, 9·6-20·0; p<0·0001). The most common (≥1%) adverse events were protein in urine (8 [1%] of 668 participants in the rimepegant group vs 7 [1%] of 674 participants in the placebo group), nausea (7 [1%] of 668 vs 18 [3%] of 674), and urinary tract infection (5 [1%] of 668 vs 8 [1%] of 674). There were no rimegepant-related serious adverse events.Among adults living in China or South Korea, a single dose of 75 mg rimegepant was effective for the acute treatment of migraine. Safety and tolerability were similar to placebo. Our findings suggest that rimegepant might be a useful new addition to the range of medications for the acute treatment of migraine in China and South Korea, but further studies are needed to support long-term efficacy and safety and to compare rimegepant with other medications for the acute treatment of migraine in this population.BioShin Limited.For the Chinese and Korean translations of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
aefs发布了新的文献求助10
刚刚
芯芯完成签到,获得积分10
1秒前
2秒前
4秒前
5秒前
安戈发布了新的文献求助10
8秒前
ei123应助chai采纳,获得10
8秒前
小汪同学完成签到,获得积分10
10秒前
芯芯发布了新的文献求助30
10秒前
11秒前
yufanhui应助11100采纳,获得10
11秒前
charles完成签到,获得积分10
12秒前
12秒前
良猫完成签到,获得积分10
12秒前
学fei了吗完成签到,获得积分10
13秒前
18969431868完成签到,获得积分10
14秒前
dd完成签到,获得积分10
15秒前
深情安青应助奔跑的苕皮采纳,获得10
17秒前
南陌完成签到 ,获得积分10
18秒前
无花果应助zhongxianghua采纳,获得10
18秒前
木子yuchen完成签到 ,获得积分10
19秒前
欢喜千风完成签到,获得积分20
20秒前
22秒前
roc221完成签到,获得积分20
22秒前
23秒前
科研大手完成签到,获得积分10
23秒前
25秒前
25秒前
28秒前
roc221发布了新的文献求助10
28秒前
zzz发布了新的文献求助10
29秒前
pluto应助leo采纳,获得10
29秒前
30秒前
ZHY2023发布了新的文献求助10
30秒前
31秒前
细腻的荆发布了新的文献求助10
32秒前
33秒前
哔哔鱼完成签到,获得积分10
35秒前
白水完成签到,获得积分10
37秒前
volvoamg发布了新的文献求助10
39秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 800
Ethnicities: Media, Health, and Coping 700
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3086199
求助须知:如何正确求助?哪些是违规求助? 2739042
关于积分的说明 7552885
捐赠科研通 2388936
什么是DOI,文献DOI怎么找? 1266730
科研通“疑难数据库(出版商)”最低求助积分说明 613551
版权声明 598592